by HOPA
The landscape of hematology/oncology pharmacy continues to evolve. Join a select group of industry experts as they discuss initiatives aimed at growing and advancing the field of hematology/oncology pharmacy. Whether you are hematology/oncology pharmacist, pharmacy intern, resident, fellow, student, technician, or administrator, this informative podcast is for you.
Language
🇺🇲
Publishing Since
2/26/2020
Email Addresses
1 available
Phone Numbers
0 available
August 27, 2021
<p><em><span style="font-weight: 400;">HOPA Now</span></em> <span style="font-weight: 400;">is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.</span></p> <p> </p> <p><span style="font-weight: 400;">These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.</span></p> <p> </p> <p><span style="font-weight: 400;">In this episode of</span> <em><span style="font-weight: 400;">HOPA Now,</span></em> <span style="font-weight: 400;">Dr. Lisa Holle discusses genitourinary cancer clinical pearls, including bladder cancer survival benefit options such as split dose treatments, primary treatment options for early and late-stage renal cancers, bone modifying agent recommendations for patients with bone metastases and management for asymptomatic patients.</span></p> <p> </p> <p><span style="font-weight: 400;">In this episode you will learn:</span></p> <p> </p> <p><strong>Genitourinary Cancers: Top 10 Clinical Pearls</strong></p> <ul> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Bladder cancer survival benefit options, including split-dose treatments</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">The relationship between vitamin B12 deficiencies and bladder resections</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">The primary treatment of early-stage renal cancer with one exception</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Criteria for the treatment of stage 4 renal cancer</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Bone-modifying agent recommendations for renal cancer</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Management for asymptomatic, early-stage prostate cancer patients</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Relugolix as an ADT option in some prostate cancers</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Considerations for treatment of relapsed or refractory prostate cancer patients</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Dosing of bone-modifying agents used in prostate cancer patients</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Radiation therapy recommendations based on cancer stages</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Preferred chemotherapy for nonseminoma and seminoma</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Bleomycin pulmonary toxicity</span></li> </ul> <p> </p> <p><strong>Mentioned in This Episode:</strong></p> <p><a href="http://www.hoparx.org/"><span style= "font-weight: 400;">HOPA</span></a></p> <p> </p> <p><strong>Quotes:</strong></p> <p> </p> <p><span style="font-weight: 400;">“In early-stage renal cancer, no established role exists for adjuvant therapy except in patients with stage 3 renal cell cancer of clear cell histology and high risk for relapse.” — Dr. Lisa Holle</span></p> <p> </p> <p><span style="font-weight: 400;">“Bone-modifying agents are recommended for renal cell cancer patients with bone metastases.” — Dr. Lisa Holle</span></p> <p> </p> <p><span style="font-weight: 400;">“Early-stage prostate cancer patients have a very high rate of 10-year survival.” — Dr. Lisa Holle</span></p> <p><br /> <br /></p>
August 27, 2021
<p><em><span style="font-weight: 400;">HOPA Now</span></em> <span style="font-weight: 400;">is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.</span></p> <p> </p> <p><span style="font-weight: 400;">These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.</span></p> <p> </p> <p><span style="font-weight: 400;">In this episode of</span> <em><span style="font-weight: 400;">HOPA Now,</span></em> <span style="font-weight: 400;">Dr. Daniel Melzer highlights the top ten clinical pearls regarding various forms and stages of lung cancer and the treatment options for these different disease diagnoses. He also shares chemotherapy treatments and survival rates and other considerations that can help determine future therapy options in various diagnosis situations.</span></p> <p> </p> <p><span style="font-weight: 400;">In this episode you will learn:</span></p> <p> </p> <p><strong>Lung Cancer Considerations and Treatments</strong></p> <ul> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Stage four non-small cell lung cancer targeted therapy guidelines</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Diagnoses in which treatment must be an immunotherapy plus chemotherapy combination</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Metastatic disease considerations for first- and second-line setting situations</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">The importance of histology when determining if a patient needs targeted therapy</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Chemotherapy treatment options and survival rates for stage one, two, and three cancer patients</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">How first-line treatment for small cell lung cancer depends on staging</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Timing of relapse considerations to help determine future therapy options</span></li> </ul> <p> </p> <p><strong>Mentioned in This Episode:</strong></p> <p><a href="http://www.hoparx.org/"><span style= "font-weight: 400;">HOPA</span></a></p> <p> </p> <p><strong>Tweetables:</strong></p> <p> </p> <p><span style="font-weight: 400;">“There is a higher overall rate of survival in patients that receive pembrolizumab in the first-line setting.” — Daniel Melzer</span></p> <p> </p> <p><span style="font-weight: 400;">“In stage two and stage three patients, there is a survival benefit in receiving chemotherapy versus observation.” — Daniel Melzer</span></p> <p> </p> <p><span style="font-weight: 400;">“First-line treatment for small cell lung cancer depends on staging.” — Daniel Melzer</span></p>
October 8, 2020
<p><em><span style="font-weight: 400;">HOPA Now</span></em> <span style="font-weight: 400;">is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.</span></p> <p> </p> <p><span style="font-weight: 400;">These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.</span></p> <p> </p> <p><span style="font-weight: 400;">In this episode of</span> <em><span style="font-weight: 400;">HOPA Now,</span></em> <span style="font-weight: 400;">Dr. Allison Baxley covers the high points of the pathology, diagnostic workup, and biology of GI cancers, including colon cancers, exocrine pancreatic cancers, upper GI cancers, gastric cancers, and hepatocellular carcinoma. She covers testing and recommendations, demographics and risk factors, the role of genetics, staging locations, and distinct variations between these various GI cancers.</span></p> <p> </p> <p><span style="font-weight: 400;">In this episode, you will learn:</span></p> <p> </p> <p><strong>Gastrointestinal Cancers Fundamentals</strong></p> <ul> <li style="font-weight: 400;"><span style="font-weight: 400;">The basic pathophysiology and common genetic predisposition of colon cancers</span></li> <li style="font-weight: 400;"><span style= "font-weight: 400;">Recommendations for testing at various stages at colon cancers, including those with metastatic disease</span></li> <li style="font-weight: 400;"><span style="font-weight: 400;">BRAF testing and recommendations and common patient response</span></li> <li style="font-weight: 400;"><span style= "font-weight: 400;">Considerations for diagnostic workup and staging process that may affect treatment decisions during early-stage disease</span></li> <li style="font-weight: 400;"><span style="font-weight: 400;">An overview of exocrine pancreatic cancers origination, prognosis, staging decisions and treatment options</span></li> <li style="font-weight: 400;"><span style="font-weight: 400;">The role of genetics in pancreatic cancers and recommendations for chemotherapy and PARP inhibitors</span></li> <li style="font-weight: 400;"><span style="font-weight: 400;">Upper GI cancers including esophageal, gastric, and esophagogastric junction cancers and their histologics</span></li> <li style="font-weight: 400;"><span style= "font-weight: 400;">Distinct variations between the geography, demographics and risk factors of adenocarcinomas and squamous cell carcinomas in esophageal cancers</span></li> <li style="font-weight: 400;"><span style= "font-weight: 400;">Staging locations and clinical trials for EG junction tumors</span></li> <li style="font-weight: 400;"><span style= "font-weight: 400;">Specific hereditary risk factors for gastric cancer</span></li> <li style="font-weight: 400;"><span style="font-weight: 400;">A brief overview of hepatocellular carcinoma including demographics, risk factors, and pathologic types</span></li> </ul> <p> </p> <p><strong>Mentioned in This Episode:</strong></p> <p><a href="http://www.hoparx.org/"><span style= "font-weight: 400;">HOPA</span></a></p> <p> </p> <p><strong>Quotes:</strong></p> <p> </p> <p><span style="font-weight: 400;">“All colon cancer patients should be tested for MSI and MMR status.” — Dr. Allison Baxley</span></p> <p> </p> <p><span style="font-weight: 400;">“In patients with early-stage disease, there are several things during the diagnostic workup and staging process that may affect treatment decisions.” — Dr. Allison Baxley</span></p> <p> </p> <p><span style="font-weight: 400;">“For gastric cancer specifically, there are several hereditary risk factors that put a patient at higher risk.” — Dr. Allison Baxley</span></p> <p> </p>
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.